X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (89) 89
humans (84) 84
female (79) 79
oncology (66) 66
breast cancer (57) 57
middle aged (56) 56
adult (53) 53
aged (52) 52
breast neoplasms - drug therapy (42) 42
cancer (42) 42
breast neoplasms - pathology (36) 36
chemotherapy (30) 30
life sciences (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
aged, 80 and over (22) 22
treatment outcome (22) 22
care and treatment (21) 21
antineoplastic combined chemotherapy protocols - adverse effects (20) 20
disease-free survival (19) 19
metastasis (18) 18
breast neoplasms - genetics (17) 17
breast neoplasms - metabolism (17) 17
breast neoplasms - mortality (16) 16
hematology, oncology and palliative medicine (16) 16
prognosis (16) 16
research (16) 16
survival (16) 16
health aspects (15) 15
therapy (15) 15
trastuzumab (15) 15
analysis (14) 14
male (14) 14
receptor, erbb-2 - metabolism (14) 14
chemotherapy, adjuvant (13) 13
mutation (13) 13
neoplasm staging (13) 13
studies (13) 13
survival analysis (13) 13
taxoids - administration & dosage (13) 13
antineoplastic agents (12) 12
drug administration schedule (12) 12
paclitaxel (12) 12
retrospective studies (12) 12
tumors (12) 12
women (12) 12
antimitotic agents (11) 11
clinical trials (11) 11
receptor, erbb-2 - genetics (11) 11
research article (11) 11
adjuvant treatment (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
bevacizumab (10) 10
genetic aspects (10) 10
genetics (10) 10
adjuvant chemotherapy (9) 9
antineoplastic agents - therapeutic use (9) 9
cancer therapies (9) 9
docetaxel (9) 9
fluorouracil - administration & dosage (9) 9
genomics (9) 9
neoplasm metastasis (9) 9
physiological aspects (9) 9
risk factors (9) 9
breast neoplasms - surgery (8) 8
capecitabine (8) 8
chemical sciences (8) 8
combined modality therapy (8) 8
dose-response relationship, drug (8) 8
drug therapy (8) 8
dyes (8) 8
expression (8) 8
her2 (8) 8
medicine & public health (8) 8
metastases (8) 8
oncology, experimental (8) 8
polymorphism, single nucleotide (8) 8
prospective studies (8) 8
skin and connective tissue diseases (8) 8
time factors (8) 8
toxicity (8) 8
young adult (8) 8
breast neoplasms - chemistry (7) 7
cancer patients (7) 7
carcinoma (7) 7
cohort studies (7) 7
combination (7) 7
deoxycytidine - analogs & derivatives (7) 7
efficacy (7) 7
fluorouracil - adverse effects (7) 7
follow-up (7) 7
genomes (7) 7
lymphatic metastasis (7) 7
medicine (7) 7
patients (7) 7
radiotherapy (7) 7
angiogenesis (6) 6
antibodies, monoclonal, humanized - administration & dosage (6) 6
biomarkers (6) 6
brain metastases (6) 6
breast neoplasms (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2006, Volume 355, Issue 26, pp. 2733 - 2743
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 933 - 942
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2008, Volume 112, Issue 3, pp. 533 - 543
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 741 - 748
Summary Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer.... 
Hematology, Oncology and Palliative Medicine | ONCOLOGY | FOLLOW-UP | CHEMOTHERAPY | Breast Neoplasms - surgery | Predictive Value of Tests | Breast Neoplasms - secondary | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Neoplasms, Second Primary | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | France | Heart Diseases - chemically induced | Radiotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Early Detection of Cancer | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Antimitotic agents | Care and treatment | Clinical trials | Breast cancer | Product development | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1269 - 1278
Journal Article
by Nik-Zainal, Serena and Davies, Helen and Staaf, Johan and Ramakrishna, Manasa and Glodzik, Dominik and Zou, Xueqing and Martincorena, Inigo and Alexanov, Ludmil B and Martin, Sancha and Wedge, David C and van Loo, Peter and Ju, Young Seok and Smid, Marcel and Brinkman, Arie B and Morganella, Sano and Aure, Miriam R and Lingjærde, Ole Christian and Langerød, Anita and Ringnér, Markus and Ahn, Sung-Min and Boyault, Sanine and Brock, Jane E and Broeks, Annegien and Butler, Adam and Desmedt, Christine and Dirix, Luc and nov, Serge and Fatima, Aquila and Foekens, John A and Gerstung, Moritz and Hooijer, Gerrit K. J and Jang, Se Jin and Jones, David R and Kim, Hyung-Yong and King, Tari A and Krishnamurthy, Savitri and Lee, Hee Jin and Lee, Jeong-Yeon and Li, Yilong and McLaren, Stuart and Menzies, Anew and Mustonen, Ville and O'Meara, Sarah and Pauporté, Iris and Pivot, Xavier and Purdie, Colin A and Raine, Keiran and Ramakrishnan, Kamna and Roíguez-González, F. Germán and Romieu, Gilles and Sieuwerts, Anieta M and Simpson, Peter T and Shepherd, Rebecca and Stebbings, Lucy and Stefansson, Olafur A and Teague, Jon and Tommasi, Stefania and Treilleux, Isabelle and van den Eynden, Gert G and Vermeulen, Peter and Vincent-Salomon, Anne and Yates, Lucy and Caldas, Carlos and van't Veer, Laura and Tutt, Anew and Knappskog, Stian and Tan, Benita Kiat Tee and Jonkers, Jos and Borg, Åke and Ueno, Naoto T and Sotiriou, Christos and Viari, Alain and Futreal, P. Anew and Campbell, Peter J and Span, Paul N and van Laere, Steven and Lakhani, Sunil R and Eyfjord, Jorunn E and Thompson, Alastair M and Birney, Ewan and Stunnenberg, Henik G and van de Vijver, Marc J and Martens, John W. M and Børresen-Dale, Anne-Lise and Richardson, Anea L and Kong, Gu and Thomas, Gilles and Stratton, Michael R and Los Alamos National Lab. (LANL), Los Alamos, NM (United States) and Onkologi och Patologi, MV and Familial Breast Cancer and Lund University and MEMEG and Oncology and Pathology, MV and BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation and Lunds universitet and Familjär bröstcancer
Nature, ISSN 0028-0836, 2016, Volume 534, Issue 7605, pp. 47 - +
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 20, pp. 3239 - 3247
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
EFFICACY | ONCOLOGY | RANDOMIZED PHASE-II | TAMOXIFEN RESISTANCE | GROWTH | MCF-7 CELLS | COMBINATION | INHIBITOR | EXPRESSION | ESTROGEN-RECEPTOR | PLUS | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2013, Volume 31, Issue 14, pp. 1719 - 1725
Journal Article